ARNA
$35.74
Arena Pharmaceutical
($.20)
(.56%)
ARNA
Earnings Whisper ®
N/A
3rd Quarter September 2018
Consensus:  ($0.72)
Revenue:  $0.93 Mil
Monday
Nov 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ARNA reports earnings?
Beat
Meet
Miss

Where is ARNA's stock price going from here?
Up
Flat
Down
Stock chart of ARNA
Analysts
Summary of analysts' recommendations for ARNA
Score
Grade
Pivots
Resistance
$36.80
$36.47
$36.10

$35.77

Support
$35.41
$35.08
$34.71
Tweet
Growth
Description
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsEndo International plcJohnson & JohnsonMylanPerrigoUltragenyx PharmaceuticalBristol-Myers Squibb